


AL/OE-TR-1994-0070



**ARMSTRONG  
LABORATORY**

**ACUTE TOXICITY EVALUATION OF  
HALON REPLACEMENT  
TRIFLUOROIODOMETHANE (CF<sub>3</sub>I)**

**E. R. Kinhead  
S. A. Salins  
R. E. Wolfe  
H. F. Leahy**

**MANTECH ENVIRONMENTAL TECHNOLOGY, INC.  
P.O. BOX 31009  
DAYTON, OH 45437**

**J. H. English**

**OCCUPATIONAL AND ENVIRONMENTAL HEALTH DIRECTORATE  
TOXICOLOGY DIVISION, ARMSTRONG LABORATORY  
WRIGHT-PATTERSON AFB, OH 45433-7400**

**February 1994**

**19960208 111**

**FINAL REPORT FOR THE PERIOD AUGUST THROUGH DECEMBER 1993**

**Approved for public release; distribution is unlimited**

**AIR FORCE MATERIEL COMMAND  
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433-6573**

**DTIC QUALITY INSPECTED 1**

## NOTICES

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Armstrong Laboratory. Additional copies may be purchased from:

National Technical Information Service  
5285 Port Royal Road  
Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Center  
Cameron Station  
Alexandria, Virginia 22314

### DISCLAIMER

This Technical Report is published as received and has not been edited by the Technical Editing Staff of the Armstrong Laboratory.

### TECHNICAL REVIEW AND APPROVAL


AL/OE-TR-1994-0070

The experiments reported herein were conducted according to the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animal Resources, National Research Council.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE COMMANDER

  
TERRY A. CHILDRRESS, Lt Col, USAF, BSC  
Director, Toxicology Division  
Armstrong Laboratory

**REPORT DOCUMENTATION PAGE**

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave Blank)</b>		<b>2. REPORT DATE</b> February 1994	<b>3. REPORT TYPE AND DATES COVERED</b> Final - August-December 1993	
<b>4. TITLE AND SUBTITLE</b> Acute Toxicity Evaluation of Halon Replacement Trifluoroiodomethane (CF <sub>3</sub> I)			<b>5. FUNDING NUMBERS</b> Contract F33615-90-C-0532 PE 62202F PR 6302 TA 630200 WU 63020002	
<b>6. AUTHOR(S)</b>  E.R. Kinkead, S.A. Salins, R.E. Wolfe, and H.F. Leahy				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> ManTech Environmental Technology, Inc. Toxic Hazards Research Unit P.O. Box 31009 Dayton, OH 45437-0009			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>  4300-9403	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Armstrong Laboratory, Occupational and Environmental Health Directorate Toxicology Division, Human Systems Center Air Force Materiel Command Wright-Patterson AFB OH 45433-7400			<b>10. SPONSORING; MONITORING AGENCY REPORT NUMBER</b>  AL/OE-TR-1994-0070	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION/AVAILABILITY STATEMENT</b> Approved for public release; distribution is unlimited.			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 words)</b>  Trifluoroiodomethane (CF <sub>3</sub> I) is being considered as a replacement compound for Halon 1301. The material would be used as a flooding agent for in-flight aircraft and electronic equipment fires and for fire extinguishment in confined spaces. A series of 4-h nose-only inhalation exposures were performed on F-344 rats at 1.0 and 0.5% CF <sub>3</sub> I. No signs of toxic stress were noted during or following exposure. Inhalation of CF <sub>3</sub> I at concentrations of 1.0 or 0.5% in the atmosphere did not result in any observable toxicological effects.				
<b>14. SUBJECT TERMS</b> Halon 1301 Trifluoroiodomethane CF <sub>3</sub> I			<b>15. NUMBER OF PAGES</b>  18	
Fire Extinguishant Thyroxine			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> UNCLASSIFIED	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> UNCLASSIFIED	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> UNCLASSIFIED	<b>20. LIMITATION OF ABSTRACT</b>  UL	

THIS PAGE INTENTIONALLY LEFT BLANK

## PREFACE

This is one of a series of technical reports describing results of the experimental laboratory programs conducted at the Toxic Hazards Research Unit, ManTech Environmental Technology, Inc. This document serves as a final report on the acute toxicity evaluation of halon replacement trifluoroiodomethane (CF<sub>3</sub>I). The research described in this report began in August 1993 and was completed in September 1993 under Department of the Air Force Contract No. F33615-90-C-0532 (Study No. F25). Lt Col Terry A. Childress served as Contract Technical Monitor for the U.S. Air Force, Armstrong Laboratory.

The animals used in this study were handled in accordance with the principles stated in the *Guide for the Care and Use of Laboratory Animals*, prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, Department of Health and Human Services, National Institute of Health Publication #86-23, 1985, and the Animal Welfare Act of 1966, as amended.

## TABLE OF CONTENTS

SECTION	PAGE
PREFACE . . . . .	1
LIST OF TABLES . . . . .	3
ABBREVIATIONS . . . . .	4
1 INTRODUCTION . . . . .	5
2 MATERIALS AND METHODS . . . . .	6
Test Compound . . . . .	6
Test Animals . . . . .	6
Generation and Analysis of Exposure Atmospheres . . . . .	6
Exposure Regimen . . . . .	7
Toxicity Assessments . . . . .	7
Statistical Analysis . . . . .	7
3 RESULTS . . . . .	9
Exposure System Analysis . . . . .	9
Inhalation Toxicology . . . . .	9
4 DISCUSSION . . . . .	15
5 REFERENCES . . . . .	16

## LIST OF TABLES

TABLE	PAGE
1 Tissues Harvested from Control and CF <sub>3</sub> I-Exposed F-344 Rats for Histopathologic Examination . . . . .	8
2 Serum Chemistry and Whole Blood Assessments from Control and CF <sub>3</sub> I-Exposed F-344 Rats . . . . .	8
3 Analysis of CF <sub>3</sub> I Concentrations Inhaled by Male F-344 Rats . . . . .	9
4 Mean Body Weights of Male F-344 Rats Exposed to CF <sub>3</sub> I via Nose-Only Inhalation . . . . .	10
5 Mean Hematologic and Clinical Chemistry Values of Male Rats Sacrificed Postexposure Following a 4-h Nose-Only Exposure to CF <sub>3</sub> I . . . . .	11
6 Mean Hematologic and Clinical Chemistry Values of Male Rats Sacrificed Postexposure Following a 4-h Nose-Only Exposure to CF <sub>3</sub> I . . . . .	13

## ABBREVIATIONS

A/G	Albumin/globulin ratio
ALT	Alanine amniotransferase
AST	Aspartate amniotransferase
BW	Body weight
°C	Degrees centigrade
CF <sub>3</sub> I	Trifluoriodomethane
dL	Decaliter
F-344	Fischer 344 rats
fl	Fentaliter
g	Gram
h	Hour
HCT	Hematocrit
HGB	Hemoglobin
IU	International units
m	Meter
MBW	Mean body weight
MCH	Mean corpuscular hemoglobin
MCHC	Mean corpuscular hemoglobin concentration
MCV	Mean corpuscular volume
mm	Millimeter
N	Number
pg	Picogram
ppm	Parts per million
RBC	Red blood cell
SEM	Standard error of the mean
T <sub>4</sub>	Thyroxine
TBG	Thyroxine-binding globulin
WBC	White blood cell



## SECTION 1

### INTRODUCTION

Environmental concern over the depletion of stratospheric ozone and global warming has led to an international treaty called the Montreal Protocol (1987), which calls for the phase out of halons by the Year 2000. Presently, the Air Force is using Halon 1301 as a flooding agent for extinguishing in-flight aircraft and electronic equipment fires and for fire extinguishment in confined spaces. Because it is believed to have less ozone-depleting activity, trifluoroiodomethane ( $\text{CF}_3\text{I}$ ) is being considered as a possible replacement for Halon 1301.

Trifluoroiodomethane is not a commercial product, therefore, very little is known concerning its toxicological properties. However, based on available data from similar compounds, the inhalation  $\text{LC}_{50}$  should be quite high (greater than 10%). Because the compound has an iodine atom, it is possible that exposure might interfere with thyroid function (Thomas and Bell, 1982). To determine if inhalation of  $\text{CF}_3\text{I}$  causes changes in the thyroid or thyroid function, inhalation exposures were performed in rats, in which the thyroid hormone (thyroxine [ $\text{T}_4$ ]) was monitored during the postexposure period. Two concentrations were tested with subsequent clinical chemistry evaluations performed immediately following exposure, 3 and 14 days postexposure.

Because  $\text{CF}_3\text{I}$  is not being produced commercially at this time, it is scarce and relatively expensive. To reduce the amount of test compound required to perform these toxicologic evaluations, a nose-only chamber was employed. Chamber volume and air flow are greatly reduced using this apparatus compared to a whole-body exposure system, resulting in the use of smaller quantities of the test material.

This study was intended to evaluate the potential toxicity of  $\text{CF}_3\text{I}$  following short-term, high-concentration inhalation exposures in rats. It was also designed to determine if changes in the endocrine system occurred following the inhalation exposure regimen.

## SECTION 2

### MATERIALS AND METHODS

#### **Test Compound**

The CF<sub>3</sub>I (CAS 2314-97-8) used in this study was purchased from PCR, Inc., Gainesville, FL. The compound has a formula weight of 195.91 and a boiling point of -22.5 °C. The compound is a liquid and is stored in a cylinder under pressure.

#### **Test Animals**

Ninety male Fischer 344 (F-344) rats were purchased from Charles River Breeding Laboratories, Raleigh, NC. The rats were 6 weeks of age upon arrival and 8 weeks of age at the time of exposure. All rats were identified by tail tattoo and were subjected to a 2-week quarantine period. Water and feed (Purina Formulab #5008) were available ad libitum, except during exposure. Animal room temperatures were maintained at 21 to 25 °C, and the light/dark cycle was set at 12-h intervals. The animals were group housed (2 per cage, except during exposure) in clear plastic cages with wood chip bedding (Beta-Chip, Northeastern Products Corp., Warrensburg, NY). The animals used in this study were handled in accordance with the principles stated in the *Guide for the Care and Use of Laboratory Animals*, prepared by the U.S. Department of Health and Human Services (1985).

#### **Generation and Analysis of Exposure Atmospheres**

Trifluoroiodomethane vapor was generated from a cylinder partially submersed in a controlled water bath maintained at 22 °C. The vapor concentration was controlled using a calibrated Matheson rotameter (Matheson Gas Products, Secaucus, NJ) to measure the volume of gas delivered to a known volume-dilution air input stream. The chamber atmosphere was analyzed using a Varian 3400 gas chromatograph (Varian Associates, Palo Alto, CA) equipped with a loop injection system with a flame ionizing detector. A 15-m x 0.53-mm wide bore, fused silica capillary column coated with SPB-5 was used. The column temperature was isothermal at 50 °C. The analysis samples were taken from a centrally located port. The system was programmed to inject once per minute and cycle every 5 min followed by integration, printout of area data, and start of a new cycle. This method provided for near continuous analysis of the exposure chamber atmosphere.

The nose-only chamber is a stainless-steel flow past chamber as described by Cannon et al., 1983. The chamber has 52 ports; 30 were randomly selected for rat exposure. Plexiglas rat restraining tubes that extended radially outward were plugged into the ports.

### **Exposure Regimen**

Each nose-only exposure duration was for 4-h. The exposure groups of 30 rats each were divided into 2 interim sacrifice groups and 1 final sacrifice group of 10 rats each. Interim sacrifices occurred immediately following exposure and at 3 days postexposure. A final sacrifice occurred at 14 days postexposure. A total of 30 F-344 rats were included in each of 3 exposures, at 1.00%, 0.50%, and an air control.

### **Toxicity Assessments**

Records were maintained of body weights (BW), signs of toxicity, and mortality. Euthanasia was via halothane inhalation overdose. At sacrifice, gross pathology was performed on all animals, and tissues were harvested for histopathologic examination (Table 1). Tissues were fixed in 10% neutral buffered formalin, trimmed, and further processed via routine methods for hematoxylin-eosin-stained paraffin-embedded sections (Luna, 1968). Additionally, blood was drawn for select hematology and clinical chemistry assays (Table 2). Erythrocytes were enumerated on a Coulter counter (Coulter Electronics, Hialeah, FL), and sera for clinical chemistry evaluations were assayed on an Ektachem 700XR (Eastman Kodak, Rochester, NY). Thyroxine and thyroxine-binding globulin (TBG) assays were performed using a DuPont ACA analyzer (DuPont Co., Wilmington, DE).

### **Statistical Analysis**

Comparisons of postexposure BW gains were performed using the repeated multivariate analysis of variance with Scheffe pairwise comparisons (Barcikowski, 1983). A two-factorial (dose and time) analysis of variance with multivariate comparisons was used to analyze the hematology and clinical chemistry data. Histopathology results were analyzed using the Fischer's Exact Test (Zar, 1974).

**TABLE 1. TISSUES HARVESTED FROM CONTROL AND CF<sub>3</sub>I-EXPOSED F-344 RATS FOR HISTOPATHOLOGIC EXAMINATION**

---

Gross Lesions	Spleen
Heart	Thyroid
Lungs	Kidneys
Trachea	Adrenals
Liver	Nasal Cavity
Parathyroid	

---

**TABLE 2. SERUM CHEMISTRY AND WHOLE BLOOD ASSESSMENTS FROM CONTROL AND CF<sub>3</sub>I-EXPOSED F-344 RATS**

---

Albumin
Thyroxine-binding globulin (TBG)
Thyroxine (T <sub>4</sub> )
Alanine aminotransaminase (ALT)
Aspartate aminotransaminase (AST)
Globulin
Hematocrit (HCT)
Hemoglobin
Red blood cell (RBC) count
Total and differential leukocyte count

---

### SECTION 3

#### RESULTS

##### Exposure System Analysis

The specified target concentrations of 1.00 and 0.50% CF<sub>3</sub>I were maintained during the 4-h exposure period. The exposure mean concentrations were maintained within  $\pm 6\%$  of the desired concentrations. Mean concentrations for each exposure, along with the mean high and low concentrations, are provided in Table 3.

##### Inhalation Toxicity

There were no deaths resulting from exposure. No treatment-related signs of toxic stress were noted during exposure or during the 14-day observation period. Comparison of the mean body weights (MBW) of the control and high-exposure groups indicated an initial loss in the CF<sub>3</sub>I group at 24 h followed by normal gains thereafter (Table 4). A similar loss in MBW was noted in the low-exposure group at 24 h, however, the MBW of this group continued to be less than the MBW of the other two groups throughout the 14-day postexposure observation period.

**TABLE 3. ANALYSIS OF CF<sub>3</sub>I CONCENTRATIONS INHALED BY MALE F-344 RATS**

Target Concentration (%)	1.00	0.50
Mean Concentration (%)	0.99	0.53
Standard Deviation	0.01	0.01
Maximum Concentration (%)	1.01	0.56
Minimum Concentration (%)	0.930	0.52

**TABLE 4. MEAN<sup>a</sup> BODY WEIGHTS OF MALE F-344 RATS EXPOSED TO CF<sub>3</sub>I VIA NOSE-ONLY INHALATION**

	Day (Pre- and Postexposure)			
	0	1	7	14
High Exposure	182.1 ± 2.2	178.7 ± 2.8	209.7 ± 2.4	228.4 ± 3.3
Low Exposure	187.0 ± 1.8	180.2 ± 2.0	196.8 ± 3.4	210.1 ± 3.4
Control	183.3 ± 2.1	182.5 ± 2.0	203.2 ± 3.0	222.3 ± 3.4

<sup>a</sup>Mean ± SEM, N=30 at Day 0, N=20 at Day 1, N=10 at Days 7 and 14.

The results of the hematology and clinical chemistry analyses are listed in Tables 5 and 6. Several blood parameters were found to be statistically different from control values, however, all values were within normal limits for F-344 rats. The mean TBG and T<sub>4</sub> values of the high-exposure group were statistically significantly different from the control values at 14-days postexposure. Also, the mean TBG value of the low-exposure group was different from the control group immediately following exposure. All mean values were within normal limits and not considered treatment related. Tissues examined microscopically showed no lesions of clinical or pathological significance.

TABLE 5. MEAN<sup>a</sup> HEMATOLOGIC AND CLINICAL CHEMISTRY VALUES OF MALE RATS SACRIFICED POSTEXPOSURE FOLLOWING A 4-H NOSE-ONLY EXPOSURE TO CF<sub>3</sub>I

	0 H Postexposure		3 Days Postexposure	
	High 1.0%	Control	High 1.0%	Control
RBC (X10 <sup>6</sup> /μL)	7.4 ± 0.1	7.3 ± 0.2 <sup>d</sup>	7.5 ± 0.1	7.9 ± 0.1
WBC (X10 <sup>3</sup> /μL)	3.7 ± 0.2	3.4 ± 0.2 <sup>d</sup>	6.2 ± 0.2	6.2 ± 0.2
HCT (%)	41.7 ± 0.5	41.0 ± 1.1 <sup>d</sup>	42.8 ± 0.8	43.7 ± 0.6
HGB (g/dL)	13.3 ± 0.2	13.1 ± 0.3 <sup>d</sup>	13.0 ± 0.2 <sup>c</sup>	14.1 ± 0.2
Total Protein (g/dL)	5.8 ± (0.1)	6.1 ± 0.1	6.2 ± 0.1	6.2 ± (0.1)
Albumin (g/dL)	3.1 ± (0.1)	3.3 ± (0.1)	3.4 ± (0.1)	3.4 ± (0.1)
Globulin (g/dL)	2.7 ± (0.1)	2.8 ± (0.1)	2.8 ± (0.1)	2.8 ± (0.1)
A/G ratio	1.1 ± (0.1) <sup>b</sup>	1.2 ± (0.1)	1.2 ± (0.1)	1.2 ± (0.1)
AST (IU/L)	94.9 ± 5.0	104.5 ± 8.1	160.4 ± 16.1 <sup>b</sup>	76.0 ± 1.3
ALT (IU/L)	55.7 ± 1.3 <sup>b</sup>	66.8 ± 2.3	58.8 ± 1.0	63.1 ± 1.6
TBG	37.7 ± 0.3	36.0 ± 0.5	39.3 ± 0.2	32.9 ± 0.8
T <sub>4</sub>	3.6 ± 0.1	2.9 ± 0.3	4.5 ± 0.3	3.6 ± 0.4
MCV (fl)	56.7 ± 0.2	56.2 ± 0.4 <sup>d</sup>	56.9 ± 0.3	55.1 ± 0.1
MCH (pg)	18.1 ± (0.1)	18.0 ± 0.1 <sup>d</sup>	17.3 ± 0.4	17.7 ± 0.1
MCHC (g/dL)	31.9 ± 0.1	32.0 ± 0.1 <sup>d</sup>	30.3 ± 0.7 <sup>b</sup>	32.2 ± 0.1

(continued)

TABLE 5. Continued

	14 Days Postexposure	
	High 1.0%	Control
RBC (X10 <sup>6</sup> /μL)	8.2 ± 0.1	8.4 ± 0.1
WBC (X10 <sup>3</sup> /μL)	5.7 ± 0.2 <sup>c</sup>	6.7 ± 0.3
HCT (%)	44.9 ± 0.4	45.2 ± 0.3
HGB (g/dL)	14.5 ± 0.1	15.0 ± 0.1
Total Protein (g/dL)	6.4 ± (0.1) <sup>b</sup>	5.2 ± 0.1
Albumin (g/dL)	3.5 ± (0.1) <sup>b</sup>	3.3 ± (0.1)
Globulin (g/dL)	2.9 ± (0.1)	1.9 ± (0.1)
A/G ratio	1.2 ± (0.1) <sup>b</sup>	1.7 ± (0.1)
AST (IU/L)	100.1 ± 4.6	85.8 ± 1.3
ALT (IU/L)	63.3 ± 1.2 <sup>b</sup>	54.5 ± 1.4
TBG	34.1 ± 0.7 <sup>b</sup>	38.8 ± 0.5
T <sub>4</sub>	4.3 ± 0.4 <sup>b</sup>	2.4 ± 0.2
MCV (fl)	54.6 ± 0.2	53.5 ± 0.1
MCH (pg)	17.7 ± 0.1	17.8 ± 0.1
MCHC (g/dL)	32.4 ± 0.1	33.2 ± 0.1

<sup>a</sup>Mean ± SEM, N=10.

<sup>b</sup>Significantly different than control at p<0.01.

<sup>c</sup>Significantly different than control at p<0.05.

<sup>d</sup>N=9.



**TABLE 6. MEAN<sup>a</sup> HEMATOLOGIC AND CLINICAL CHEMISTRY VALUES OF MALE RATS SACRIFICED POSTEXPOSURE FOLLOWING A 4-H NOSE-ONLY EXPOSURE TO CF<sub>3</sub>I**

	0 H Postexposure		3 Days Postexposure	
	Low 0.5%	Control	Low 0.5%	Control
RBC (X10 <sup>6</sup> /μL)	7.6 ± 0.1	7.6 ± 0.2 <sup>c</sup>	7.6 ± 0.1	7.9 ± 0.1
WBC (X10 <sup>3</sup> /μL)	3.8 ± 0.2	3.4 ± 0.2 <sup>c</sup>	5.6 ± 0.1	6.2 ± 0.2
HCT (%)	42.8 ± 0.8	41.0 ± 1.1 <sup>c</sup>	42.3 ± 0.3	43.7 ± 0.6
HGB (g/dL)	13.7 ± 0.2	13.1 ± 0.3 <sup>c</sup>	13.6 ± 0.1	14.1 ± 0.2
Total Protein (g/dL)	6.2 ± 0.1	6.1 ± 0.1	6.3 ± 0.1	6.2 ± 0.1
Albumin (g/dL)	3.4 ± 0.1	3.3 ± 0.1	3.5 ± 0.1	3.4 ± 0.1
Globulin (g/dL)	2.8 ± 0.1	2.8 ± 0.1	2.8 ± 0.1	2.8 ± 0.1
A/G ratio	1.2 ± 0.1	1.2 ± 0.1	1.2 ± 0.1	1.2 ± 0.1
AST (IU/L)	112.2 ± 5.1	104.5 ± 8.1	76.0 ± 1.3	76.0 ± 1.3
ALT (IU/L)	71.9 ± 1.4	66.8 ± 2.3	60.0 ± 1.0	63.1 ± 1.6
TBG	32.6 ± 0.8 <sup>b</sup>	36.0 ± 0.5	38.1 ± 0.4	32.9 ± 0.8
T <sub>4</sub>	3.9 ± 0.3	2.9 ± 0.3	2.4 ± 0.3	3.6 ± 0.4
MCV (fl)	56.2 ± 0.3	56.2 ± 0.4 <sup>c</sup>	56.0 ± 0.2	55.1 ± 0.1
MCH (pg)	17.9 ± 0.1	18.0 ± 0.1 <sup>c</sup>	18.0 ± 0.1	17.7 ± 0.1
MCHC (g/dL)	31.9 ± 0.2	32.0 ± 0.1 <sup>c</sup>	32.1 ± 0.1	32.2 ± 0.1

(continued)

TABLE 6. Continued

	14 Days Postexposure	
	Low 0.5%	Control
RBC (X10 <sup>6</sup> /μL)	8.3 ± 0.1	8.4 ± 0.1
WBC (X10 <sup>3</sup> /μL)	6.4 ± 0.3	6.7 ± 0.3
HCT (%)	44.3 ± 0.6	45.2 ± 0.3
HGB (g/dL)	14.9 ± 0.2	15.0 ± 0.1
Total Protein (g/dL)	5.4 ± 0.1	5.2 ± 0.1
Albumin (g/dL)	3.3 ± <0.1	3.3 ± <0.1
Globulin (g/dL)	2.1 ± <0.1 <sup>b</sup>	1.9 ± <0.1
A/G ratio	1.6 ± <0.1	1.7 ± <0.1
AST (IU/L)	95.9 ± 3.3	85.8 ± 1.3
ALT (IU/L)	58.0 ± 1.6	54.5 ± 1.4
TBG	40.5 ± 1.0	38.8 ± 0.5
T <sub>4</sub>	2.4 ± 0.2	2.4 ± 0.2
MCV (fl)	53.4 ± 0.2	53.5 ± 0.1
MCH (pg)	18.0 ± 0.1	17.8 ± 0.1
MCHC (g/dL)	33.7 ± 0.1	33.2 ± 0.1

<sup>a</sup>Mean ± SEM, N=10.

<sup>b</sup>Significantly different than control at p<0.05.

<sup>c</sup>N=9.

## SECTION 4

### DISCUSSION

Acute (4-h) inhalation of  $\text{CF}_3\text{I}$  at concentrations of 1.0 and 0.5% did not result in any signs of toxic stress during or following exposure. Histopathologic examination of tissues sampled at different time points following exposure indicated normal findings. Clinical chemistry assays following exposure showed no biologically significant differences in thyroid hormones in the circulating blood of  $\text{CF}_3\text{I}$ -treated rats when compared to control rats.

The lack of mortality in rats exposed to 10,000 ppm (1%)  $\text{CF}_3\text{I}$  would indicate that the compound could be classified as "practically non-toxic" (Deickmann and Gerarde, 1969). However, because of its extremely high vapor pressure, a greater hazard might be that of asphyxiation, if large quantities of this material were to be spilled in a confined area.

## SECTION 5

### REFERENCES

- Barcikowski, R.S.** 1983. *Computer Packages and Research Design*. Vol. 1:BMDP. Lanham, MD: University Press of America.
- Cannon, W.C., E.F. Blanton, and K.E. McDonald.** 1983. The flow-past chamber: An improved nose-only exposure system for rodents. *Am. Ind. Hyg. Assoc. J.* 44(12):923-933.
- Deickmann, W.B. and H.W. Gerarde.** 1969. *Toxicology of Drugs and Chemicals*. New York, NY: Academic Press.
- Luna, L.G.,** ed. 1968. *Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology*. Third ed. New York: McGraw-Hill.
- Thomas, J.S. and J.U. Bell.** 1982. Endocrine toxicology. In: A. Wallace Hayes, ed. *Principles and Methods of Toxicology*, p.495. New York: Raven Press.
- Zar, J.H.** 1974. *Biostatistical Analysis*. Englewood Cliffs, NJ: Prentice Hall.